Narcolepsy drug trial halted early: what happened?

NCT ID NCT06179407

Terminated Symptom relief Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an experimental drug called MK-6552 in 9 people with narcolepsy type 1, a condition that causes sudden sleep attacks. The goal was to see if the drug was safe and could help patients stay awake during the day. The trial was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

narcolepsy narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NARCOLEPSY

Contacts and locations

Locations

Bogan Sleep Consultants ( Site 0001)

Columbia, South Carolina, 29201, United States
Delta Waves, Inc. ( Site 0008)

Colorado Springs, Colorado, 80918, United States
FutureSearch Trials of Neurology ( Site 0004)

Austin, Texas, 78731, United States
NeuroTrials Research Inc ( Site 0006)

Atlanta, Georgia, 30328, United States
Teradan Clinical Trials, LLC ( Site 0005)

Brandon, Florida, 33511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.